PRIMEVAX IMMUNO-ONCOLOGY, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2015-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.primevax.com
Clinical Trials
3
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)Intratumoral Injection of PV-001-DV Plus DC in Patients With Melanoma
Phase 1
Not yet recruiting
- Conditions
- Advanced Melanoma
- First Posted Date
- 2019-06-19
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- PrimeVax Immuno-Oncology Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT03990493
Intratumoral Injection of Dengue Virus-1 #45AZ5 (PV-001-DV) in Patients With Melanoma
Phase 1
Not yet recruiting
- Conditions
- Advanced Melanoma
- First Posted Date
- 2019-06-18
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- PrimeVax Immuno-Oncology Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT03989895
Arm 1: Lysate Pulsed Dendritic Cells (PV-001-DC) in Patients With Melanoma
Phase 1
Not yet recruiting
- Conditions
- Metastatic Melanoma
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- PrimeVax Immuno-Oncology Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT03803397
News
No news found